• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

偏头痛患者的欧洲五维健康量表(EQ-5D)健康效用评分。

EuroQol (EQ-5D) health utility scores for patients with migraine.

机构信息

Department of Health Economic Statistics, Merck Research Laboratories, North Wales, PA, USA.

出版信息

Qual Life Res. 2011 May;20(4):601-8. doi: 10.1007/s11136-010-9783-5. Epub 2010 Nov 10.

DOI:10.1007/s11136-010-9783-5
PMID:21063786
Abstract

PURPOSE

Previous studies have reported health utilities for migraine patients as generally measured between migraine attacks, but health utility data for within a migraine attack are unavailable. We evaluated within-attack health utilities among acute migraine patients experiencing different grades of headache severity.

METHODS

We examined data for 330 20-65-year-old adults, in good physical health, who had 1-6 moderate/severe migraine attacks per month in the 2 months prior to the screening visit. Data were collected from a multicenter, double-blind study of a treatment for acute migraine in the United States. The EQ-5D system was used to measure generic health status at baseline and 24 h post-treatment within an acute migraine attack, and patients were also asked to rate their pain level at these time points (no, mild, moderate, or severe pain). The D1 time-trade-off scoring algorithm for the U.S. population was applied. Confidence intervals were estimated by bootstrap methods.

RESULTS

The study population was 88% women and 78% white ethnicity, with 60% of subjects over age 40. The disutility of mild migraine pain was estimated to be 0.140 (95% CI: 0.0848, 0.1940), with a disutility for moderate migraine pain of 0.186 (95% CI: 0.1645, 0.2053) and for severe migraine pain of 0.493 (95% CI: 0.4100, 0.5654).

CONCLUSIONS

Within-attack disutilities estimated for migraine in this study are much greater than those reported for migraine when evaluated as a chronic health condition (e.g., valuations collected at random time points). These data can be of value in adapting results from clinical trials of migraine interventions to cost-utility policy analyses.

摘要

目的

先前的研究报告称,偏头痛患者的健康效用通常是在偏头痛发作之间进行测量的,但偏头痛发作期间的健康效用数据尚不清楚。我们评估了经历不同头痛严重程度的急性偏头痛患者在发作期间的健康效用。

方法

我们检查了 330 名 20-65 岁、身体健康的成年人的数据,他们在筛选前 2 个月内每月有 1-6 次中度/重度偏头痛发作。这些数据来自美国一项急性偏头痛治疗的多中心、双盲研究。使用 EQ-5D 系统在基线和急性偏头痛发作后 24 小时内测量一般健康状况,并要求患者在这些时间点评估自己的疼痛程度(无、轻度、中度或重度疼痛)。应用了美国人群的 D1 时间权衡评分算法。置信区间通过自举方法估计。

结果

研究人群中 88%为女性,78%为白种人,60%的受试者年龄超过 40 岁。轻度偏头痛疼痛的失能值估计为 0.140(95%CI:0.0848,0.1940),中度偏头痛疼痛的失能值为 0.186(95%CI:0.1645,0.2053),重度偏头痛疼痛的失能值为 0.493(95%CI:0.4100,0.5654)。

结论

本研究中估计的偏头痛发作期间的失用值远大于慢性偏头痛健康状况评估时报告的失用值(例如,在随机时间点收集的评估值)。这些数据可以为将偏头痛干预措施的临床试验结果应用于成本效用政策分析提供价值。

相似文献

1
EuroQol (EQ-5D) health utility scores for patients with migraine.偏头痛患者的欧洲五维健康量表(EQ-5D)健康效用评分。
Qual Life Res. 2011 May;20(4):601-8. doi: 10.1007/s11136-010-9783-5. Epub 2010 Nov 10.
2
Mapping from disease-specific measures to health-state utility values in individuals with migraine.将偏头痛患者的疾病特异性测量指标转换为健康状态效用值。
Value Health. 2012 May;15(3):485-94. doi: 10.1016/j.jval.2011.12.007. Epub 2012 Feb 9.
3
EQ-5D™-derived utility values for different levels of migraine severity from a UK sample of migraineurs.基于英国偏头痛患者样本,不同偏头痛严重程度的 EQ-5D™ 效用值。
Health Qual Life Outcomes. 2012 Jun 12;10:65. doi: 10.1186/1477-7525-10-65.
4
Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant.将偏头痛特异性生活质量映射到接受利马曲班治疗的患者的健康状态效用中。
Adv Ther. 2021 Oct;38(10):5209-5220. doi: 10.1007/s12325-021-01897-2. Epub 2021 Aug 29.
5
Comparison of FACT- and EQ-5D-based utility scores in cancer.癌症患者 FACT 和 EQ-5D 量表效用评分的比较。
Value Health. 2012 Mar-Apr;15(2):305-11. doi: 10.1016/j.jval.2011.11.029. Epub 2012 Feb 2.
6
Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered Exhalation Delivery System (Sumatriptan Nasal Powder) vs Oral Sumatriptan.随机COMPASS研究中AVP - 825呼吸驱动呼气给药系统(舒马曲坦鼻粉)与口服舒马曲坦在多次偏头痛发作中的早期疗效及反应一致性
Headache. 2017 Jun;57(6):862-876. doi: 10.1111/head.13105. Epub 2017 May 11.
7
An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study.一项关于肉毒毒素 A 治疗慢性偏头痛的真实世界应用的开放性前瞻性研究:REPOSE 研究。
J Headache Pain. 2019 Mar 7;20(1):26. doi: 10.1186/s10194-019-0976-1.
8
Randomized, controlled trial of telcagepant over four migraine attacks.随机、对照试验:telcagepant 治疗四次偏头痛发作。
Cephalalgia. 2010 Dec;30(12):1443-57. doi: 10.1177/0333102410370878. Epub 2010 Jun 8.
9
Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease.随机、对照研究替利加群酯治疗偏头痛合并冠状动脉疾病患者的疗效。
Headache. 2012 Feb;52(2):224-35. doi: 10.1111/j.1526-4610.2011.02052.x. Epub 2012 Jan 6.
10
An open-label trial of a sumatriptan auto-injector for migraine in patients currently treated with subcutaneous sumatriptan.一项舒马曲坦自动注射器治疗正在接受皮下舒马曲坦治疗的偏头痛患者的开放性试验。
Headache. 2013 Jan;53(1):118-125. doi: 10.1111/j.1526-4610.2012.02295.x. Epub 2012 Nov 13.

引用本文的文献

1
Cost-Utility Analysis of Erenumab Compared to Topiramate for Preventive Therapy of Migraine in Iran.伊朗依瑞奈单抗与托吡酯用于偏头痛预防性治疗的成本-效用分析
Iran J Pharm Res. 2024 Sep 16;23(1):e146026. doi: 10.5812/ijpr-146026. eCollection 2024 Jan-Dec.
2
Health-related quality of life among women and men living with migraine: a Canada-wide cross-sectional study.患有偏头痛的女性和男性的健康相关生活质量:一项加拿大全国性的横断面研究。
J Headache Pain. 2024 Oct 9;25(1):170. doi: 10.1186/s10194-024-01882-4.
3
Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer's Disease in the United States.

本文引用的文献

1
On the (not so) constant proportional trade-off in TTO.TTO 中的(并非那么)恒定比例权衡。
Qual Life Res. 2010 May;19(4):489-97. doi: 10.1007/s11136-010-9605-9. Epub 2010 Feb 12.
2
Methods for measuring temporary health States for cost-utility analyses.用于成本效益分析的临时健康状态测量方法。
Pharmacoeconomics. 2009;27(9):713-23. doi: 10.2165/11317060-000000000-00000.
3
Quality of life after a subtrochanteric fracture: a prospective cohort study on 87 elderly patients.高龄股骨转子下骨折患者 87 例的前瞻性队列研究:生活质量分析。
估算在美国使用多奈单抗对早期有症状阿尔茨海默病进行限期治疗的经济合理价格。
Neurol Ther. 2024 Dec;13(6):1641-1659. doi: 10.1007/s40120-024-00649-y. Epub 2024 Sep 18.
4
Headache in patients with non-functioning pituitary adenoma before and after transsphenoidal surgery - a prospective study.经蝶窦手术后无功能垂体腺瘤患者头痛的前瞻性研究。
Pituitary. 2024 Oct;27(5):635-643. doi: 10.1007/s11102-024-01401-3. Epub 2024 May 20.
5
The use of clinical scales and PROMs in headache disorders and migraine, summarizing their dissemination and operationalization.临床量表和患者报告结局量表在头痛疾病和偏头痛中的应用,总结其传播和实施情况。
Heliyon. 2023 May 13;9(5):e16187. doi: 10.1016/j.heliyon.2023.e16187. eCollection 2023 May.
6
Assessing the Role of Infant and Toddler MenACWY Immunisation in the UK: Does the Adolescent MenACWY Programme Provide Sufficient Protection?评估婴幼儿MenACWY疫苗接种在英国的作用:青少年MenACWY疫苗接种计划是否提供了足够的保护?
Vaccines (Basel). 2023 May 4;11(5):940. doi: 10.3390/vaccines11050940.
7
A Path to Improved Alzheimer's Care: Simulating Long-Term Health Outcomes of Lecanemab in Early Alzheimer's Disease from the CLARITY AD Trial.改善阿尔茨海默病护理的途径:从CLARITY AD试验模拟lecanemab在早期阿尔茨海默病中的长期健康结局
Neurol Ther. 2023 Jun;12(3):863-881. doi: 10.1007/s40120-023-00473-w. Epub 2023 Apr 2.
8
Estimated Societal Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling.使用模拟模型评估早期阿尔茨海默病患者中lecanemab的社会价值。
Neurol Ther. 2023 Jun;12(3):795-814. doi: 10.1007/s40120-023-00460-1. Epub 2023 Mar 16.
9
Prevalence and Burden of Migraine in Switzerland: Cross-Sectional Study in ten Specialised Headache Centres from the BECOME Study.瑞士偏头痛的患病率与负担:来自BECOME研究的十个专业头痛中心的横断面研究
Pain Ther. 2023 Apr;12(2):575-591. doi: 10.1007/s40122-023-00484-3. Epub 2023 Feb 26.
10
A Digital Therapeutic Allowing a Personalized Low-Glycemic Nutrition for the Prophylaxis of Migraine: Real World Data from Two Prospective Studies.一种用于偏头痛预防的个性化低血糖营养的数字治疗:来自两项前瞻性研究的真实世界数据。
Nutrients. 2022 Jul 17;14(14):2927. doi: 10.3390/nu14142927.
Injury. 2009 Apr;40(4):371-6. doi: 10.1016/j.injury.2008.09.010. Epub 2009 Feb 18.
4
Relative efficiency of the EQ-5D, HUI2, and HUI3 index scores in measuring health burden of chronic medical conditions in a population health survey in the United States.在美国一项人群健康调查中,EQ-5D、HUI2和HUI3指数评分在衡量慢性疾病健康负担方面的相对效率。
Med Care. 2009 Jan;47(1):53-60. doi: 10.1097/MLR.0b013e31817d92f8.
5
Quality of life after a stable trochanteric fracture--a prospective cohort study on 148 patients.稳定型转子间骨折后的生活质量——一项针对148例患者的前瞻性队列研究
J Orthop Trauma. 2009 Jan;23(1):39-44. doi: 10.1097/BOT.0b013e318191f5e4.
6
Migraine frequency and health utilities: findings from a multisite survey.偏头痛频率与健康效用:一项多中心调查的结果
Value Health. 2008 Mar-Apr;11(2):315-21. doi: 10.1111/j.1524-4733.2007.00246.x.
7
The migraine cycle: patient burden of migraine during and between migraine attacks.偏头痛周期:偏头痛发作期间及发作间期患者的偏头痛负担
Headache. 2008 Mar;48(3):430-41. doi: 10.1111/j.1526-4610.2007.01004.x. Epub 2007 Dec 28.
8
The impact of topiramate on health-related quality of life indicators in chronic migraine.托吡酯对慢性偏头痛患者健康相关生活质量指标的影响。
Headache. 2007 Nov-Dec;47(10):1398-408. doi: 10.1111/j.1526-4610.2007.00950.x.
9
Health-related quality of life in women with symptomatic hand osteoarthritis: a comparison with rheumatoid arthritis patients, healthy controls, and normative data.有症状的手部骨关节炎女性的健康相关生活质量:与类风湿关节炎患者、健康对照者及标准数据的比较。
Arthritis Rheum. 2007 Dec 15;57(8):1404-9. doi: 10.1002/art.23079.
10
Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial.托吡酯6个月偏头痛预防性治疗的停药与继续治疗(PROMPT):一项随机、双盲、安慰剂对照试验
Lancet Neurol. 2007 Dec;6(12):1054-62. doi: 10.1016/S1474-4422(07)70272-7. Epub 2007 Nov 7.